<DOC>
	<DOCNO>NCT01333228</DOCNO>
	<brief_summary>Endothelial Progenitor Cells ( EPC ) represent small cellular population bone marrow peripheral blood cell . EPCs recruit injured tissue play important role regeneration reparation . Experimental clinical data suggest EPCs hepatoprotective activity could improve liver regeneration acute chronic liver injury . The aim project evaluate safety therapeutic effect autologous bone marrow-derived EPCs , administer hepatic artery patient advance liver cirrhosis .</brief_summary>
	<brief_title>Evaluate Safety Efficacy Autologous Bone Marrow-derived Endothelial Progenitor Cells Advanced Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Liver cirrhosis ( ChildPugh 8 ) . Ability sign inform consent Age &lt; 18 &gt; 75 Variceal bleed severe infection within past 30 day screen Chronic encephalopathy prevent ability sign inform consent ( could do legal representant patient ) and/or ability follow study protocol Hepatocellular carcinoma ( previous current ) Any current previous malignancy ( within 5 year inclusion ) except `` situ '' tumor skin basal cell carcinomas Any severe extrahepatic disease past 30 day inclusion Any current decompensated chronic disease Any contraindication examination clinical protocol ( medullar aspiration , arteriography , HVPG measurement ) Any condition could negatively affect compliance protocol Pregnant breastfeed woman Participation trial experimental drug device within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>